Noll L Campbell1,2,3,4,5, Anthony J Perkins4, Babar A Khan2,3,4,5,6, Sujuan Gao2,3,6, Mark O Farber6, Sikandar Khan2,3,6, Sophia Wang6,7, Malaz A Boustani2,3,4,5,6. 1. Purdue University College of Pharmacy, West Lafayette, Indiana. 2. Indiana University Center for Aging Research, Indianapolis, Indiana. 3. Regenstrief Institute, Inc, Indianapolis, Indiana. 4. Indiana University Center for Health Innovation and Implementation Science and Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana. 5. Sandra Eskenazi Center for Brain Care Innovation at Eskenazi Health, Indianapolis, Indiana. 6. Department of Medicine Indiana University School of Medicine, Indianapolis, Indiana. 7. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana.
Abstract
OBJECTIVE:Benzodiazepines and anticholinergics are risk factors for delirium in the intensive care unit (ICU). We tested the impact of a deprescribing intervention on short-term delirium outcomes. DESIGN: Multisite randomized clinical trial. SETTING: ICUs of three large hospitals. PARTICIPANTS: Two hundred adults aged 18 years or older and admitted to an ICU with delirium, according to the Richmond Agitation-Sedation Scale and the Confusion Assessment Method for the ICU (CAM-ICU). Participants had a contraindication to haloperidol (seizure disorder or prolonged QT interval) or preference against haloperidol as a treatment for delirium, and were excluded for serious mental illness, stroke, pregnancy, or alcohol withdrawal. Participants were randomized to a deprescribing intervention or usual care. The intervention included electronic alerts combined with pharmacist support to deprescribe anticholinergics and benzodiazepines. MEASUREMENTS: Primary outcomes were delirium duration measured by the CAM-ICU and severity measured by the Delirium Rating Scale Revised-98 (DRS-R-98) and the CAM-ICU-7; secondary outcomes included adverse events and mortality. RESULTS:Participants had a mean age of 61.8 (SD = 14.3) years, 59% were female, and 52% were African American, with no significant differences in baseline characteristics between groups. No differences between groups were identified in the number exposed to anticholinergics (P = .219) or benzodiazepines (P = .566), the median total anticholinergic score (P = .282), or the median total benzodiazepine dose in lorazepam equivalents (P = .501). Neither median delirium/coma-free days (P = .361) nor median change in delirium severity scores (P = .582 for DRS-R-98; P = .333 for CAM-ICU-7) were different between groups. No differences in adverse events or mortality were identified. CONCLUSIONS: When added to state-of-the-art clinical services, this deprescribing intervention had no impact on medication use in ICU participants. Given the age of the population, results of clinical outcomes may not be easily extrapolated to older adults. Nonetheless, improved approaches for deprescribing or preventing anticholinergics and benzodiazepines should be developed to determine the impact on delirium outcomes. J Am Geriatr Soc 67:695-702, 2019.
RCT Entities:
OBJECTIVE:Benzodiazepines and anticholinergics are risk factors for delirium in the intensive care unit (ICU). We tested the impact of a deprescribing intervention on short-term delirium outcomes. DESIGN: Multisite randomized clinical trial. SETTING: ICUs of three large hospitals. PARTICIPANTS: Two hundred adults aged 18 years or older and admitted to an ICU with delirium, according to the Richmond Agitation-Sedation Scale and the Confusion Assessment Method for the ICU (CAM-ICU). Participants had a contraindication to haloperidol (seizure disorder or prolonged QT interval) or preference against haloperidol as a treatment for delirium, and were excluded for serious mental illness, stroke, pregnancy, or alcohol withdrawal. Participants were randomized to a deprescribing intervention or usual care. The intervention included electronic alerts combined with pharmacist support to deprescribe anticholinergics and benzodiazepines. MEASUREMENTS: Primary outcomes were delirium duration measured by the CAM-ICU and severity measured by the Delirium Rating Scale Revised-98 (DRS-R-98) and the CAM-ICU-7; secondary outcomes included adverse events and mortality. RESULTS:Participants had a mean age of 61.8 (SD = 14.3) years, 59% were female, and 52% were African American, with no significant differences in baseline characteristics between groups. No differences between groups were identified in the number exposed to anticholinergics (P = .219) or benzodiazepines (P = .566), the median total anticholinergic score (P = .282), or the median total benzodiazepine dose in lorazepam equivalents (P = .501). Neither median delirium/coma-free days (P = .361) nor median change in delirium severity scores (P = .582 for DRS-R-98; P = .333 for CAM-ICU-7) were different between groups. No differences in adverse events or mortality were identified. CONCLUSIONS: When added to state-of-the-art clinical services, this deprescribing intervention had no impact on medication use in ICU participants. Given the age of the population, results of clinical outcomes may not be easily extrapolated to older adults. Nonetheless, improved approaches for deprescribing or preventing anticholinergics and benzodiazepines should be developed to determine the impact on delirium outcomes. J Am Geriatr Soc 67:695-702, 2019.
Authors: E W Ely; R Margolin; J Francis; L May; B Truman; R Dittus; T Speroff; S Gautam; G R Bernard; S K Inouye Journal: Crit Care Med Date: 2001-07 Impact factor: 7.598
Authors: E W Ely; S K Inouye; G R Bernard; S Gordon; J Francis; L May; B Truman; T Speroff; S Gautam; R Margolin; R P Hart; R Dittus Journal: JAMA Date: 2001-12-05 Impact factor: 56.272
Authors: Curtis N Sessler; Mark S Gosnell; Mary Jo Grap; Gretchen M Brophy; Pam V O'Neal; Kimberly A Keane; Eljim P Tesoro; R K Elswick Journal: Am J Respir Crit Care Med Date: 2002-11-15 Impact factor: 21.405
Authors: E W Ely; S Gautam; R Margolin; J Francis; L May; T Speroff; B Truman; R Dittus; R Bernard; S K Inouye Journal: Intensive Care Med Date: 2001-11-08 Impact factor: 17.440
Authors: Babar A Khan; Anthony J Perkins; Nagendra K Prasad; Anantha Shekhar; Noll L Campbell; Sujuan Gao; Sophia Wang; Sikandar H Khan; Edward R Marcantonio; Homer L Twigg; Malaz A Boustani Journal: Crit Care Med Date: 2020-03 Impact factor: 7.598
Authors: Elizabeth Colantuoni; Mounica Koneru; Narjes Akhlaghi; Ximin Li; Mohamed D Hashem; Victor D Dinglas; Karin J Neufeld; Michael O Harhay; Dale M Needham Journal: Trials Date: 2021-05-20 Impact factor: 2.279
Authors: Heidi Lindroth; Babar A Khan; Janet S Carpenter; Sujuan Gao; Anthony J Perkins; Sikandar H Khan; Sophia Wang; Richard N Jones; Malaz A Boustani Journal: Ann Am Thorac Soc Date: 2020-09
Authors: Noll L Campbell; Richard J Holden; Qing Tang; Malaz A Boustani; Evgenia Teal; Jennifer Hillstrom; Wanzhu Tu; Daniel O Clark; Christopher M Callahan Journal: J Am Geriatr Soc Date: 2021-03-26 Impact factor: 7.538
Authors: Joshua D Niznik; Brendan J Collins; Lori T Armistead; Claire K Larson; Casey J Kelley; Tamera D Hughes; Kimberly A Sanders; Rebecca Carlson; Stefanie P Ferreri Journal: Res Social Adm Pharm Date: 2021-07-16